- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Biological E Corbevax offers better immunity as heterologous booster shot
CORBEVAX can be administered as a booster six months after two doses of COVAXIN or COVISHIELD for all adults.
New Delhi: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the virus. Earlier, countries were administering homologous booster shots. However, a heterologous booster was cleared by several countries, including the US, UK, Israel, etc., for emergency use as it showed increased immunity levels and was more effective compared to homologous shots.
A study by Lancet on the effectiveness of heterologous and homologous boosters showed that the heterologous booster offers higher protection than the homologous booster. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies.
Recently, the Indian government approved the emergency use of the COVID-19 vaccine CORBEVAX as a heterologous booster shot for all adults, making it the first such vaccine in India. Biological E's CORBEVAX is safer and induces better neutralization antibodies against different variants of COVID-19 as a heterologous booster shot.
CORBEVAX can be administered as a booster six months after two doses of COVAXIN or COVISHIELD for all adults. Administering the CORBEVAX vaccine as a heterologous booster dose provides significant enhancement in immune response and excellent safety profile in people who have already taken two doses of either COVIDHSIELD or COVAXIN.
BE had undertaken a multi-centre Phase III placebo-controlled heterologous booster clinical trial among fully vaccinated 416 subjects aged 18 to 80 years. The CORBEVAX heterologous booster achieved a 5.5 to 6.7 fold (geometric mean fold rise) rise in neutralizing antibody titres. Subjects tested for neutralizing antibodies against Omicron also showcased a significant increase in antibody titres after receiving CORBEVAX as a heterologous booster shot. About 75 to 91% of these subjects showed neutralizing antibodies against Omicron Variant. The trial concluded that the CORBEVAX booster dose is safe and well tolerated, with no serious or grade 3 adverse events or adverse events of special interest during the three months of the follow-up period.
Dr. M. Raja Rao, Medical Superintendent of Gandhi Hospital, said, "India has managed the pandemic and ensuing healthcare crisis with coordinated efforts among the government, industry, and healthcare providers. An effective vaccination policy has prevented further waves of the spread of COVID-19. However, given the peculiar nature of the disease and mutations of the virus, there is a need for additional layers of protection against infection. Introducing heterologous booster shots is a step toward a much more scientific and time-sensitive vaccine policy.
Heterologous booster is a preferred choice for booster dose because it offers effectiveness against variants (Delta and Omicron), and improves cellular immune response (significant Th1 skew response)."
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751